Company research
Freenome, Inc.
CIK 2017526Updated Sep 24, 2026
SecurityFRNM · NASDAQ · equity
Historical securities (1)
PCSC · NASDAQ · equity · closed Jul 20, 2026Name history
Perceptive Capital Solutions Corp · through Jul 15, 2026
FRNM price & chart
Loading TradingView…
NASDAQ:FRNM on TradingView ↗About the company
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's development of SimpleScreen™ CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation among millions of at-risk individuals. For more information, visit www.freenome.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 92,779,988Source | 89,899,087Source |
| Current assets: | ||
| Assets, CurrentUSD | 907,570Source | 1,244,690Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 5,704,244Source | 3,660,811Source |
| Stockholders’ equity: | ||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -4,796,919Source | -2,116,366Source |
| Stockholders' Equity Attributable to ParentUSD | -4,796,674Source | -2,116,121Source |
| Liabilities and EquityUSD | 92,779,988Source | 89,899,087Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 2,254,244Source | 210,811Source |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 2,254,244Source | 210,811Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -864,653Source | — |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 600,000Source | — |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 0Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 865,031Source | 1,129,684Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 2,980,553Source | — |
| Investment Income, InterestUSD | 3,821,319Source | — |
| Net Income (Loss) Attributable to ParentUSD | 837,468Source | — |
| Nonoperating Income (Expense)USD | 3,818,021Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | -3,298Source | — |
income statement · annual statements
| Line item | FY 2025 |
|---|---|
| Operating Income (Loss)USD | -2,980,553Source |
| Net Income (Loss) Attributable to ParentUSD | 837,468Source |
| Additional Financial Items | |
| General and Administrative ExpenseUSD | 2,980,553Source |
| Investment Income, InterestUSD | 3,821,319Source |
| Nonoperating Income (Expense)USD | 3,818,021Source |
Offerings
Registration 333-298423
Registration 333-295377
- Offering amount
- $240.0
- Offering price
- market-price
- Ticker
- PCSC
Registration 333-295377-01
- Offering amount
- $240.0
- Offering price
- market-price
- Ticker
- PCSC
Filing attachments
ny20080283_ex107.htm · S-1 · 2026-08-18
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-1 (Form Type) Freenome, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Notes Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Fee Rate Amount of Registration Fee …
Read attachment ↗ef20080133_ex99-1.htm · 8-K/A · 2026-08-13
EX-99.1 2 ef20080133_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FREENOME HOLDINGS, INC. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except shares and par value data) June 30, 2026 December 31, 2025 ──────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗ef20080133_ex99-2.htm · 8-K/A · 2026-08-13
EX-99.2 3 ef20080133_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of the financial condition and results of operations of Freenome Inc. (“New Freenome,”, “we,” “us,” and “our”) should be read in conjunction with our unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2026 and 2025, and the audited consolidated f…
Read attachment ↗ef20078829_ex99-1.htm · 8-K · 2026-07-27
EX-99.1 2 ef20078829_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. - Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening - - Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening - BRISBANE, Calif. and ABBOTT PARK, Ill. (July 27, 2026) - Freenome, Inc. (Nasdaq:…
Read attachment ↗ef20078324_ex99-1.htm · 8-K · 2026-07-24
EX-99.1 19 ef20078324_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the “Form 8-K”) filed with the Securities and Exchange Commission (the “SEC”) on July 23, 2026. Unless the context otherwise requires, the “Company” refers to Freenome, Inc. (“New Freenome”) (f/k/a Perceptive Capital Solutions Corp.) and its subsid…
Read attachment ↗ef20078324_ex99-2.htm · 8-K · 2026-07-24
EX-99.2 20 ef20078324_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection - Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol “FRNM” on July 21, 2026 - - Gross proceeds to Freenome totaled more than $300 million through a PIPE, led by Perceptive Advisors and RA Capital, and funds held by Perceptive Capital Solutions Corp’s trust account - - Capital will support …
Read attachment ↗